| Q64083252 | Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations |
| Q36234034 | Effect of oral glucocorticoid intake on autonomic cardiovascular control |
| Q99572690 | Elimination profiles of betamethasone after different administration routes: evaluation of the reporting level and washout periods to ensure safe therapeutic administrations |
| Q37801536 | Evidence on Ergogenic Action of Glucocorticoids as a Doping Agent Risk |
| Q54457853 | Glucocorticoids improve high-intensity exercise performance in humans. |
| Q92050992 | Glucocorticoids in elite sport: current status, controversies and innovative management strategies-a narrative review |
| Q55054628 | Identification and characterization of impurities of tetracosactide by capillary electrophoresis and liquid chromatography coupled to time-of-flight mass spectrometry. |
| Q30424438 | Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. |
| Q47830103 | Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD. |
| Q90482431 | Regulation of Red Blood Cell Volume with Exercise Training |
| Q58590483 | Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects |
| Q43294428 | Short-term glucocorticoid intake improves exercise endurance in healthy recreationally trained women |
| Q28301349 | Simultaneous quantification and qualification of synacthen in plasma |
| Q61811010 | Single dose prednisolone alters endocrine and haematologic responses and exercise performance in men |
| Q86966265 | Therapeutic glucocorticoid administration alters the diurnal pattern of dehydroepiandrosterone |
| Q47898535 | Why glucocorticosteroids should remain in the list of prohibited substances: a sports medicine viewpoint |